JP2017535521A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535521A5 JP2017535521A5 JP2017516516A JP2017516516A JP2017535521A5 JP 2017535521 A5 JP2017535521 A5 JP 2017535521A5 JP 2017516516 A JP2017516516 A JP 2017516516A JP 2017516516 A JP2017516516 A JP 2017516516A JP 2017535521 A5 JP2017535521 A5 JP 2017535521A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- modified release
- release formulation
- beta
- lactamase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462061507P | 2014-10-08 | 2014-10-08 | |
| US62/061,507 | 2014-10-08 | ||
| US201562126556P | 2015-02-28 | 2015-02-28 | |
| US62/126,556 | 2015-02-28 | ||
| US201562205443P | 2015-08-14 | 2015-08-14 | |
| US62/205,443 | 2015-08-14 | ||
| PCT/US2015/054606 WO2016057744A1 (en) | 2014-10-08 | 2015-10-08 | Beta-lactamase formulations and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535521A JP2017535521A (ja) | 2017-11-30 |
| JP2017535521A5 true JP2017535521A5 (enExample) | 2018-11-15 |
| JP6672277B2 JP6672277B2 (ja) | 2020-04-01 |
Family
ID=55653744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516516A Active JP6672277B2 (ja) | 2014-10-08 | 2015-10-08 | ベータラクタマーゼ製剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10105322B2 (enExample) |
| EP (1) | EP3204495B1 (enExample) |
| JP (1) | JP6672277B2 (enExample) |
| KR (1) | KR102467968B1 (enExample) |
| CN (1) | CN107148473B (enExample) |
| AU (1) | AU2015330937B2 (enExample) |
| CA (1) | CA2962959C (enExample) |
| ES (1) | ES2806426T3 (enExample) |
| MX (1) | MX2017004473A (enExample) |
| WO (1) | WO2016057744A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6803328B2 (ja) | 2014-08-28 | 2021-01-06 | シンセティック バイオロジクス，インコーポレイテッド | 大腸菌ベースでのベータラクタマーゼ生産 |
| WO2016105498A1 (en) | 2014-12-23 | 2016-06-30 | Synthetic Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
| EP3261662B1 (en) | 2015-02-23 | 2021-07-21 | Synthetic Biologics Inc. | Carbapenemases for use with antibiotics for the protection of the intestinal microbiome |
| AU2016229976B2 (en) | 2015-03-06 | 2021-11-11 | Theriva Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
| JP7516007B2 (ja) | 2016-06-28 | 2024-07-16 | セリバ・バイオロジクス・インコーポレイテッド | 経口抗生物質からのマイクロバイオーム防御 |
| CN116270991A (zh) * | 2016-11-01 | 2023-06-23 | 合成生物制品有限公司 | 用于减弱抗生素抗性的方法和组合物 |
| SG10201609137PA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Gamma-polyglutamic acid and zinc compositions |
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| WO2018175414A1 (en) * | 2017-03-21 | 2018-09-27 | Synthetic Biologics, Inc. | Beta-lactamase formulations |
| JP7223015B2 (ja) * | 2017-10-25 | 2023-02-15 | ダ・ヴォルテッラ | β－ラクタマーゼ変異体 |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| AU2019320483A1 (en) * | 2018-08-05 | 2021-02-18 | Da Volterra | Compositions for the treatment of graft versus host disease |
| ES3023261T3 (en) * | 2019-05-06 | 2025-05-30 | Theriva Biologics Inc | Beta-lactamase compositions for treatment of graft versus host disease |
| US11705245B2 (en) * | 2020-03-10 | 2023-07-18 | AI:ON Innovations, Inc. | System and methods for mammalian transfer learning |
| CN112137984B (zh) * | 2020-10-30 | 2023-02-03 | 四川制药制剂有限公司 | 头孢克洛胶囊及其制备工艺 |
| WO2023168316A1 (en) * | 2022-03-04 | 2023-09-07 | Michael Ogburn | Enteric coated dry powdered cannabinoid formulations |
| CN116790567B (zh) * | 2022-12-30 | 2026-03-17 | 扬州大学 | 来源于土壤宏基因组的β-内酰胺酶及其应用 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL197650A (enExample) | 1954-05-29 | |||
| US2941995A (en) | 1957-08-02 | 1960-06-21 | Beecham Res Lab | Recovery of solid 6-aminopenicillanic acid |
| US2982696A (en) | 1959-05-01 | 1961-05-02 | Schenley Ind Inc | Ion-exchange procedures for the purification of penicillinase |
| US3070511A (en) | 1960-02-10 | 1962-12-25 | Lepetit Spa | Process for preparing 6-aminopenicillanic acid |
| US3150059A (en) | 1962-12-26 | 1964-09-22 | Lilly Co Eli | Penicillin deacylation via actinoplanaceae fermentation |
| US3239394A (en) | 1964-06-15 | 1966-03-08 | Merck & Co Inc | Process for producing 7-amino-cephalosporanic acid |
| US3499909A (en) | 1966-05-18 | 1970-03-10 | Koninklijke Gist Spiritus | Process for production of 6-aminopenicillanic acid |
| US3488729A (en) | 1966-08-22 | 1970-01-06 | Lilly Co Eli | Cephalothin ester |
| GB1241844A (en) | 1968-08-23 | 1971-08-04 | Beecham Group Ltd | Penicillins |
| GB1463513A (en) | 1974-08-13 | 1977-02-02 | Beecham Group Ltd | Enzymes |
| FI59265C (fi) | 1974-08-13 | 1981-07-10 | Beecham Group Ltd | Foerfarande foer framstaellning av 6-aminopenicillansyra |
| US4537776A (en) | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| GB2199582A (en) | 1987-01-07 | 1988-07-13 | Bayer Ag | Analogues of pancreatic secretory trypsin inhibitor |
| FR2613624B1 (fr) | 1987-04-10 | 1990-11-23 | Roussy Inst Gustave | Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines |
| CA2007083A1 (en) | 1989-01-09 | 1990-07-09 | Nobuhiko Katunuma | Pharmaceutical use of trypstatin |
| JP2813809B2 (ja) * | 1989-06-19 | 1998-10-22 | 武田薬品工業株式会社 | 有核顆粒製剤およびその製造法 |
| CS275231B2 (en) | 1989-09-29 | 1992-02-19 | Ustav Makormolekularni Chemie | Medicine bottle |
| FI920206A0 (fi) * | 1992-01-17 | 1992-01-17 | Pekka Untamo Heino | Medicinsk anvaendning, medicinskt foerfarande och preparat. |
| CZ289804B6 (cs) * | 1994-07-08 | 2002-04-17 | Astrazeneca Ab | Multijednotková tabletovaná dávková forma I |
| JPH08143476A (ja) * | 1994-11-18 | 1996-06-04 | Japan Tobacco Inc | 薬物放出制御膜及び固形製剤 |
| WO1997003185A1 (en) | 1995-07-07 | 1997-01-30 | Novo Nordisk A/S | Production of proteins using bacillus incapable of sporulation |
| KR100554924B1 (ko) * | 1998-05-18 | 2006-03-03 | 다케다 야쿠힌 고교 가부시키가이샤 | 구강내 붕괴 정제 |
| KR100536783B1 (ko) * | 1998-07-28 | 2005-12-14 | 다케다 야쿠힌 고교 가부시키가이샤 | 급속 붕해성 고체 제제 |
| FI4533U1 (fi) * | 2000-03-14 | 2000-08-10 | Finnzymes Oy | Entsyymikoostumus maidon käsittelemiseksi |
| US7585674B2 (en) | 2001-05-29 | 2009-09-08 | Kao Corporation | Host microorganisms |
| FI112666B (fi) | 2001-11-06 | 2003-12-31 | Ipsat Therapies Oy | Itiöimätön Bacillus subtilis, sen valmistus ja käyttö |
| FR2843302B1 (fr) | 2002-08-09 | 2004-10-22 | Centre Nat Rech Scient | Forme galenique pour la delivrance colique de principes actifs |
| JP4749660B2 (ja) * | 2002-10-16 | 2011-08-17 | 武田薬品工業株式会社 | 安定な固形製剤 |
| EP1564286A1 (en) | 2004-02-11 | 2005-08-17 | Université de Liège | Hybrid proteins of beta-lactamase class A |
| AR051946A1 (es) * | 2004-11-05 | 2007-02-21 | Wyeth Corp | Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina |
| DK1883396T3 (da) | 2005-05-18 | 2013-10-07 | Centre Nat Rech Scient | Afgivelse af adsorptionsmidler til tyktarmen |
| EA020867B1 (ru) * | 2006-03-06 | 2015-02-27 | Поузен Инк. | Лекарственные формы для введения комбинаций лекарственных средств |
| FI119190B (fi) | 2006-06-21 | 2008-08-29 | Ipsat Therapies Oy | Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi |
| US8273376B2 (en) * | 2006-11-17 | 2012-09-25 | Da Volterra | Colonic delivery of metallo-dependent enzymes |
| FI119678B (fi) | 2006-11-28 | 2009-02-13 | Ipsat Therapies Oy | Beta-laktamaasin käyttö |
| US9023352B2 (en) | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
| JP2013525488A (ja) * | 2010-05-03 | 2013-06-20 | アプタリス ファーマ リミテッド | 消化酵素混合物を含有するパンクレアチンを含むマイクロペレット組成物 |
| FI20105572A0 (fi) * | 2010-05-24 | 2010-05-24 | Prevab R Lcc | Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt |
| JP6017423B2 (ja) * | 2011-07-26 | 2016-11-02 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | Ｎｄｍ阻害剤 |
| CA2758556A1 (en) * | 2011-11-17 | 2013-05-17 | Pharmascience Inc. | Pharmaceutical composition of amphetamine mixed salts |
| CA2857457C (en) * | 2011-11-30 | 2018-05-01 | Takeda Pharmaceutical Company Limited | Dry coated tablet |
| US20140128431A1 (en) | 2012-04-03 | 2014-05-08 | Hoffmann-Laroche Inc. | Pharmaceutical composition with improved bioavailability, safety and tolerability |
| JP6685925B2 (ja) * | 2014-04-17 | 2020-04-22 | シンセティック バイオロジクス，インコーポレイテッド | 治療用として改善された特性を有するβ−ラクタマーゼ |
| WO2016105498A1 (en) * | 2014-12-23 | 2016-06-30 | Synthetic Biologics, Inc. | Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics |
| AU2016229976B2 (en) * | 2015-03-06 | 2021-11-11 | Theriva Biologics, Inc. | Safe and effective beta-lactamase dosing for microbiome protection |
-
2015
- 2015-10-08 KR KR1020177012353A patent/KR102467968B1/ko active Active
- 2015-10-08 US US14/878,155 patent/US10105322B2/en active Active
- 2015-10-08 CA CA2962959A patent/CA2962959C/en active Active
- 2015-10-08 AU AU2015330937A patent/AU2015330937B2/en active Active
- 2015-10-08 EP EP15849110.0A patent/EP3204495B1/en active Active
- 2015-10-08 WO PCT/US2015/054606 patent/WO2016057744A1/en not_active Ceased
- 2015-10-08 JP JP2017516516A patent/JP6672277B2/ja active Active
- 2015-10-08 ES ES15849110T patent/ES2806426T3/es active Active
- 2015-10-08 MX MX2017004473A patent/MX2017004473A/es unknown
- 2015-10-08 CN CN201580059890.6A patent/CN107148473B/zh active Active
-
2018
- 2018-08-24 US US16/111,477 patent/US10828260B2/en active Active
-
2020
- 2020-09-28 US US17/034,534 patent/US12178917B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013141534A (ru) | Составы l-ментола, состоящие из множества частиц, и связанные с ними способы | |
| EP3154523A1 (en) | Formulation for oral administration containing mesalazine | |
| JP2008280351A5 (enExample) | ||
| JP2013520467A5 (enExample) | ||
| RU2013106514A (ru) | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи | |
| JP2016535030A5 (enExample) | ||
| HRP20211269T1 (hr) | Kompozicije prolijeka na bazi monometil fumarata | |
| CN107753462A (zh) | 用于保护生物活性剂的基质和层组合物 | |
| EP2034974A2 (en) | Lipoic acid pellets | |
| SI2773348T1 (en) | PHARMACEUTICAL COMPOSITION OF OMEPRAZOLE | |
| JP2019513800A5 (enExample) | ||
| US20140178468A1 (en) | Multiparticulate extended-release composition of mesalamine | |
| JP2017532369A5 (enExample) | ||
| EP3445340A1 (en) | Oral pharmaceutical compositions of mesalazine | |
| RU2015143891A (ru) | Фармацевтические составы тамсулозина или его солей | |
| KR20200084329A (ko) | 신규한 전달 체계 | |
| JP2023509675A5 (enExample) | ||
| RU2006137660A (ru) | Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423) | |
| JP2019513801A5 (enExample) | ||
| JP2019534046A5 (enExample) | ||
| US20100172972A1 (en) | Enteric coated pharmaceutical compositions | |
| JP2017008001A5 (enExample) | ||
| WO2018108939A3 (de) | Feste pharmazeutische orale darreichungsform mit verlängerter wirkstofffreisetzung umfassend mirabegron | |
| JP2016501226A5 (enExample) | ||
| ES2900975T3 (es) | Preparación farmacéutica oral con revestimiento entérico que comprende fumarato de dimetilo |